Chemioterapia adiuvante del carcinoma del colon-retto.

Translated title of the contribution: Adjuvant chemotherapy of colorectal carcinoma

P. Casali, L. Licitra, E. Alafaci, L. Gennari

Research output: Contribution to journalArticle

Abstract

Clinical studies on adjuvant chemotherapy in colorectal cancer started 30 years ago, but some proof of its effectiveness did not come until recently. Only randomized prospective studies can provide definite evidence in this regard. Obviously, the potential value of an effective adjuvant treatment for a frequent disease such as colorectal cancer is enormous. Randomized studies had failed to provide evidence in favour of adjuvant chemotherapy in colon cancer until a recently reported study on 5-fluorouracil and levamisole. As of today, the latter regimen may be considered as the reference one for adjuvant chemotherapy in Dukes C colon cancer. In rectal cancer some studies displayed statistically significant results in favour of adjuvant chemotherapy: however, sufficient data are still unavailable to support adjuvant chemotherapy as standard treatment. On the contrary, postoperative radiotherapy is definitely effective in decreasing local relapses. Studies are underway on the combination of chemotherapy and radiotherapy in rectal cancer. In addition to systemic chemotherapy, portal infusion of cytotoxic drugs has been tested in colorectal cancer. Controlled studies are underway, but available results would not seem to support regional treatment. Recent improvement in the chemotherapy of advanced colorectal cancer has probably occurred through the pharmacologic modulation of 5-fluorouracil by leucovorin. If this will be confirmed, one will be able to resort to more effective multidrug regimens than those tested so far and an improvement in adjuvant chemotherapy may be anticipated too.

Original languageItalian
Pages (from-to)509-513
Number of pages5
JournalAnnali Italiani di Chirurgia
Volume61
Issue number5
Publication statusPublished - Sep 1990

Fingerprint

Adjuvant Chemotherapy
Colorectal Neoplasms
Rectal Neoplasms
Fluorouracil
Colonic Neoplasms
Radiotherapy
Drug Therapy
Levamisole
Leucovorin
Combination Drug Therapy
Therapeutics
Prospective Studies
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Surgery

Cite this

Chemioterapia adiuvante del carcinoma del colon-retto. / Casali, P.; Licitra, L.; Alafaci, E.; Gennari, L.

In: Annali Italiani di Chirurgia, Vol. 61, No. 5, 09.1990, p. 509-513.

Research output: Contribution to journalArticle

Casali, P. ; Licitra, L. ; Alafaci, E. ; Gennari, L. / Chemioterapia adiuvante del carcinoma del colon-retto. In: Annali Italiani di Chirurgia. 1990 ; Vol. 61, No. 5. pp. 509-513.
@article{46a54baa73724cceaf9267e72a0cee03,
title = "Chemioterapia adiuvante del carcinoma del colon-retto.",
abstract = "Clinical studies on adjuvant chemotherapy in colorectal cancer started 30 years ago, but some proof of its effectiveness did not come until recently. Only randomized prospective studies can provide definite evidence in this regard. Obviously, the potential value of an effective adjuvant treatment for a frequent disease such as colorectal cancer is enormous. Randomized studies had failed to provide evidence in favour of adjuvant chemotherapy in colon cancer until a recently reported study on 5-fluorouracil and levamisole. As of today, the latter regimen may be considered as the reference one for adjuvant chemotherapy in Dukes C colon cancer. In rectal cancer some studies displayed statistically significant results in favour of adjuvant chemotherapy: however, sufficient data are still unavailable to support adjuvant chemotherapy as standard treatment. On the contrary, postoperative radiotherapy is definitely effective in decreasing local relapses. Studies are underway on the combination of chemotherapy and radiotherapy in rectal cancer. In addition to systemic chemotherapy, portal infusion of cytotoxic drugs has been tested in colorectal cancer. Controlled studies are underway, but available results would not seem to support regional treatment. Recent improvement in the chemotherapy of advanced colorectal cancer has probably occurred through the pharmacologic modulation of 5-fluorouracil by leucovorin. If this will be confirmed, one will be able to resort to more effective multidrug regimens than those tested so far and an improvement in adjuvant chemotherapy may be anticipated too.",
author = "P. Casali and L. Licitra and E. Alafaci and L. Gennari",
year = "1990",
month = "9",
language = "Italian",
volume = "61",
pages = "509--513",
journal = "Annali Italiani di Chirurgia",
issn = "0003-469X",
publisher = "Edizioni Luigi Pozzi S.r.l.",
number = "5",

}

TY - JOUR

T1 - Chemioterapia adiuvante del carcinoma del colon-retto.

AU - Casali, P.

AU - Licitra, L.

AU - Alafaci, E.

AU - Gennari, L.

PY - 1990/9

Y1 - 1990/9

N2 - Clinical studies on adjuvant chemotherapy in colorectal cancer started 30 years ago, but some proof of its effectiveness did not come until recently. Only randomized prospective studies can provide definite evidence in this regard. Obviously, the potential value of an effective adjuvant treatment for a frequent disease such as colorectal cancer is enormous. Randomized studies had failed to provide evidence in favour of adjuvant chemotherapy in colon cancer until a recently reported study on 5-fluorouracil and levamisole. As of today, the latter regimen may be considered as the reference one for adjuvant chemotherapy in Dukes C colon cancer. In rectal cancer some studies displayed statistically significant results in favour of adjuvant chemotherapy: however, sufficient data are still unavailable to support adjuvant chemotherapy as standard treatment. On the contrary, postoperative radiotherapy is definitely effective in decreasing local relapses. Studies are underway on the combination of chemotherapy and radiotherapy in rectal cancer. In addition to systemic chemotherapy, portal infusion of cytotoxic drugs has been tested in colorectal cancer. Controlled studies are underway, but available results would not seem to support regional treatment. Recent improvement in the chemotherapy of advanced colorectal cancer has probably occurred through the pharmacologic modulation of 5-fluorouracil by leucovorin. If this will be confirmed, one will be able to resort to more effective multidrug regimens than those tested so far and an improvement in adjuvant chemotherapy may be anticipated too.

AB - Clinical studies on adjuvant chemotherapy in colorectal cancer started 30 years ago, but some proof of its effectiveness did not come until recently. Only randomized prospective studies can provide definite evidence in this regard. Obviously, the potential value of an effective adjuvant treatment for a frequent disease such as colorectal cancer is enormous. Randomized studies had failed to provide evidence in favour of adjuvant chemotherapy in colon cancer until a recently reported study on 5-fluorouracil and levamisole. As of today, the latter regimen may be considered as the reference one for adjuvant chemotherapy in Dukes C colon cancer. In rectal cancer some studies displayed statistically significant results in favour of adjuvant chemotherapy: however, sufficient data are still unavailable to support adjuvant chemotherapy as standard treatment. On the contrary, postoperative radiotherapy is definitely effective in decreasing local relapses. Studies are underway on the combination of chemotherapy and radiotherapy in rectal cancer. In addition to systemic chemotherapy, portal infusion of cytotoxic drugs has been tested in colorectal cancer. Controlled studies are underway, but available results would not seem to support regional treatment. Recent improvement in the chemotherapy of advanced colorectal cancer has probably occurred through the pharmacologic modulation of 5-fluorouracil by leucovorin. If this will be confirmed, one will be able to resort to more effective multidrug regimens than those tested so far and an improvement in adjuvant chemotherapy may be anticipated too.

UR - http://www.scopus.com/inward/record.url?scp=0025490723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025490723&partnerID=8YFLogxK

M3 - Articolo

C2 - 2100969

AN - SCOPUS:0025490723

VL - 61

SP - 509

EP - 513

JO - Annali Italiani di Chirurgia

JF - Annali Italiani di Chirurgia

SN - 0003-469X

IS - 5

ER -